How does the CLL17 trial presented at ASH 2025 change current practice guidelines?
Should all CLL patients be candidates for fixed-duration treatments?
Community PollStarted
In which patients, if any, will you choose fixed-duration treatment for CLL?
51 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · UPMC Hillman Cancer Center
Answered on
The CLL17 study provides some tangential support for time-limited therapy in a subset of patients that I would consider now--those who have low-risk disease with IGHV mutated (non-3-21) and absent TP53 mutation or deletion. Here, we would expect patients to do quite well, and long-term follow-up exi...
Join for free or sign in to see the full answer